Nathan Kline Institute for Psychiatric Research
42
4
4
30
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
11.9%
5 terminated/withdrawn out of 42 trials
85.7%
-0.8% vs industry average
17%
7 trials in Phase 3/4
60%
18 of 30 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (42)
D-serine AudRem: R33 Phase
Role: collaborator
Addressing Racial Disparities in Opioid Overdose Using Peer Recovery Coach Training and mHealth Platform
Role: collaborator
Neural and Psychiatric Consequences of Cannabis Use in Adolescents
Role: collaborator
Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
Role: lead
Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
Role: collaborator
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
Role: collaborator
Implementation of an Evidence Based Post-Traumatic Stress Disorder (PTSD) Treatment in Public Sector Settings
Role: collaborator
Ketamine in Borderline Personality Disorder
Role: collaborator
D-serine Augmentation of Neuroplasticity
Role: collaborator
Remediation of Auditory Recognition in Schizophrenia With tDCS
Role: collaborator
D-serine and Cognitive Remediation in Schizophrenia
Role: lead
Brain Activation Patterns in Schizophrenia After Computerized Cognitive Skills Training
Role: collaborator
Safety and Effectiveness of D-serine in Schizophrenia
Role: lead
Can Cognitive Training Decrease Reactive Aggression?
Role: collaborator
Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
Role: collaborator
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
Role: lead
Transcranial Direct Current Stimulation (tDCS) as a Treatment for Cognitive Deficits in Schizophrenic
Role: collaborator
Varenicline Effects In Schizophrenic Smokers
Role: lead
Evaluation of a Visual Remediation Intervention for Schizophrenia
Role: collaborator
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
Role: lead